A Non-Interventional Study of Tiotropium/Olodaterol versus Any Triple Combination Therapy for Chronic Obstructive Pulmonary Disease: The EVELUT^® Study Protocol

Figures & data

Figure 1 GOLD 2020 follow-up pharmacologic treatment recommendations.*Consider if eos ≥ 300 or eos ≥ 100 AND ≥ 2 moderate exacerbations/1 hospitalization. **Consider de-escalation of ICS or switch if pneumonia, inappropriate original indication or lack of response to ICS. ©2020, Global Initiative for Chronic Obstructive Lung Disease, reproduced with permission.¹

Abbreviations: eos, blood eosinophil count; FEV₁, forced expiratory volume in 1 second; GOLD, Global Initiative for Chronic Obstructive Lung Disease; ICS, inhaled corticosteroid; LABA, long-acting β₂-agonist; LAMA, long-acting muscarinic antagonist.

Figure 2 EVELUT^® study overview.

Abbreviations: ICS, inhaled corticosteroid; LABA, long-acting β₂-agonist; LAMA, long-acting muscarinic antagonist; V, visit.

Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2020 report). Published 2019 Available from: https://goldcopd.org/wp-content/uploads/2019/11/GOLD-2020-REPORT-ver1.0wms.pdf. Accessed 214, 2020.

 Google Scholar